Showing results (61-70 of 144) with videos related to

Sort By:
Pageof 15
Medicine|April 29, 2018
Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stagesAzahara Palomar Muñoz, José Manuel Cordero García, Mª Del Prado Talavera Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors studyJavier Sastre, Eugenio Marcuello, Bartomeu Masutti, et al.
Clinical Colorectal Cancer|April 6, 2005
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancerAlbert Abad, Alfredo Carrato, Matilde Navarro, et al.
Biochimica Et Biophysica Acta|February 9, 2016
Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumabAmanda Cañas, Laura M López-Sánchez, Jon Peñarando, et al.
Breast Cancer Research : BCR|December 11, 2012
Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumorsAmanda Cañas, Laura M López-Sánchez, Araceli Valverde-Estepa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2008
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancerEva Martinez-Balibrea, Albert Abad, Enrique Aranda, et al.
Trials|September 29, 2022
Effectiveness of the Unified Barlow Protocol (UP) and neuropsychological treatment in cancer survivors for cognitive impairments: study protocol for a randomized controlled trialFrancisco García-Torres, Adrián Tejero-Perea, Ángel Gómez-Solís, et al.
The Oncologist|August 19, 2018
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)Pilar García-Alfonso, Manuel Benavides, Esther Falcó, et al.
Cancers|July 8, 2020
Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic CancerMarta Toledano-Fonseca, M Teresa Cano, Elizabeth Inga, et al.
Cancers|April 3, 2021
The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic CancerMarta Toledano-Fonseca, M Teresa Cano, Elizabeth Inga, et al.
Pageof 15